$58.99
-0.70 (-1.17%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ANAB is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 interventional · 4 with posted results
Held by 11 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, D. E. Shaw & Co., Inc., CITADEL ADVISORS LLC, Squarepoint Ops LLC, TWO SIGMA INVESTMENTS, LP, +6 more) · FINRA short interest 7.2 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)NCT06127043Mean change in modified Mayo Score (mMs) from Baseline to Week 12Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Rosnilimab, Placebo | Ulcerative Colitis | 132 | Jan 2026 | 2025-10-03 |
| A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)NCT06041269Mean change from Baseline in 28-Joint Disease Activity Score based on CRP (DAS28-CRP) at Week 12Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Rosnilimab, Placebo | Rheumatoid Arthritis | 420 | 2024-11-29 | 2024-11-25 |
| This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).NCT05935085Proportion of subjects who achieve ≥75% reduction (improvement) from Baseline in EASI-75 as Week 14Randomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: ANB032 did not meet the primary endpoint in moderate-to-severe atopic dermatitis | Drug: ANB032, Placebo | Atopic Dermatitis Eczema | 201 | 2024-10-16actual | 2025-02-14 |
| A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia AreataNCT05205070Change from baseline in Severity of Alopecia Tool (SALT) score at Week 24Randomized · Quadruple-masked · Treatment | Phase 2 | Unknown status | Biological: Rosnilimab, Placebo | Alopecia Areata | 45 | 2023-01-19 | 2022-05-10 |
| Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)NCT03614923results2022-01-24Change From Baseline in Nasal Polyp Score (NPS) to Week 16Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Etokimab, Placebo · Drug: Mometasone Furoate Nasal Spray | Chronic Rhinosinusitis | 105 | 2020-09-02actual | 2022-01-24 |
| Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic DermatitisNCT03533751results2023-05-24Percent Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) ScoreRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Etokimab · Drug: Placebo | Atopic Dermatitis | 302 | 2019-12-03actual | 2023-05-24 |
| Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic AsthmaNCT03469934results2023-08-16Change From Baseline in Peripheral Eosinophil Count at Day 22Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Etokimab · Drug: Placebo | Eosinophilic Asthma | 25 | 2018-10-30actual | 2023-08-16 |
| Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut AllergyNCT02920021results2023-07-27Number of Participants With Treatment-emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Etokimab, Placebo | Peanut Allergy | 20 | 2018-03-30actual | 2023-07-27 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19